Puma Biotechnology (PBYI) Operating Expenses (2010 - 2026)

Puma Biotechnology (PBYI) has 17 years of Operating Expenses data on file, last reported at $48.6 million in Q1 2026.

• Quarterly Operating Expenses rose 15.75% year-over-year to $48.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $197.7 million (up 1.14% YoY) and the FY2025 annual result came in at $191.1 million, down 4.23% from the prior year.
• Operating Expenses eased to $48.6 million in Q1 2026, from $58.3 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $58.5 million in Q3 2024 to a low of $42.0 million in Q1 2025.
• A 5-year average of $49.8 million and a median of $48.4 million in 2023 frame the typical range for Operating Expenses.
• Annual changes were most pronounced in 2022 — Operating Expenses slumped 40.42% — and 2025, when it rose 27.64%.
• Tracing PBYI's Operating Expenses over 5 years: stood at $55.7 million in 2022, then advanced by 3.09% to $57.4 million in 2023, then fell by 20.33% to $45.7 million in 2024, then grew by 27.64% to $58.3 million in 2025, then slipped by 16.63% to $48.6 million in 2026.
• The last three Operating Expenses figures came in at $48.6 million (Q1 2026), $58.3 million (Q4 2025), and $44.9 million (Q3 2025), per Business Quant data.